课题基金 / 基金详情

Development of new functional artificial virus contained cancer-selective anticancer drug with the cancer-specific molecules

Development of new functional artificial virus contained cancer-selective anticancer drug with the cancer-specific molecules
开发含有癌症特异性分子的癌症选择性抗癌药物的新型功能性人工病毒
批准号:
22791255
负责人:
ONIMARU Manabu
金额:
$2.58万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Young Scientists (B)
财政年份:
2010
资助国家:
日本
项目状态:
已结题
起止时间:
2010 至 2011

项目摘要

项目成果

ONIMARU Manabu的其他基金

相似基金

相关文献

中文摘要
翻译
我们可以创造出一种含有抗癌特异性药物的多功能人工病毒。我们还在体外对这种新病毒的形态和功能进行了评估。在体外胰腺癌细胞和正常细胞的对比实验中,我们证实人工病毒已被特异性地带入胰腺癌细胞系,并具有一定的治疗效果。
英文摘要
We can create a multi-functional artificial virus contained cancer-specific anti-cancer drug. We also evaluated the form and function of this new virus in vitro. We confirmed that artificial virus had been specifically-taken into the pancreatic cancer cell line and had a certain therapeutic effect in comparative experiments in pancreatic cancer cell lines and normal cells in vitro.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Adenoviral Therapy Is More Effective in Gemcitabine-resistant Pancreatic Cancer than in Gemcitabine-sensitive Cells.
腺病毒治疗对吉西他滨耐药的胰腺癌比对吉西他滨敏感的细胞更有效。
DOI: --
发表时间:
期刊: Anticancer research. in press
影响因子: --
作者: [Takaharu Yasui, Kenoki Ohuchida, Ming Zhao, Lin Cui, Manabu Onimaru, Takuya Egami, Hayato Fujita, Takao Ohtsuka, Kazuhiro Mizumoto, Kunio Matsumoto, Masao Tanaka.]
通讯作者: Masao Tanaka.
DOI: 10.1111/j.1349-7006.2010.01783.x
发表时间: 2011-02
期刊: Cancer Science
影响因子: 5.7
作者: [T. Yasui;K. Ohuchida;Ming Zhao;M. Onimaru;Takuya Egami;H. Fujita;T. Ohtsuka;K. Mizumoto;Masao Tanaka]
通讯作者: T. Yasui;K. Ohuchida;Ming Zhao;M. Onimaru;Takuya Egami;H. Fujita;T. Ohtsuka;K. Mizumoto;Masao Tanaka
Gencitabime synergistically enhances the effect of adenovirus gene therapy through activation of the CMV promoter in
Gencitabime 通过激活 CMV 启动子来协同增强腺病毒基因治疗的效果
DOI: --
发表时间: 2010
期刊: pancreatic cancer cells Cancer Gene Ther
影响因子: --
作者: [Onimaru M, Ohuchida K, Egami T, Mizumoto K, Nagai E, Cui L, Toma H, Matsumoto K, Hashizume M, Tanaka M.]
通讯作者: Tanaka M.
Combination with low-dose gemcitabine andhTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer
与低剂量吉西他滨和 hTERT 启动子依赖性条件复制腺病毒联合使用,通过其串扰机制增强胰腺癌中的细胞毒性
DOI: --
发表时间: 2010
期刊: Cancer Lett
影响因子: 9.7
作者: [Onimaru M, Ohuchida K, Nagai E,Mizumoto K, Egami T, Tanaka M]
通讯作者: Tanaka M
6
    Elucidation of the mechanism of anti-tumor effect by disabling the immune escape mechanism and development of treatment based on regulation of the pancreatic cancer microenvironment
    • 批准号:
      20K07678
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.83万
    • 财政年份:
      2020
    • 负责人:
      ONIMARU Manabu
    • 依托单位:
    Clarification and control of immune cell-induced PSC substrate remodeling using KPCL mice
    • 批准号:
      17K10700
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.91万
    • 财政年份:
      2017
    • 负责人:
      ONIMARU Manabu
    • 依托单位:
    Elucidation of selection mechanism of disseminated cancer cells in metastatic organs
    • 批准号:
      26462064
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.16万
    • 财政年份:
      2014
    • 负责人:
      ONIMARU Manabu
    • 依托单位:
    Elucidation of the radioresistance mechanism on the microenviroment of pancreatic cancer and control of the stroma cells causing radioresistance by newly artificial virus.
    • 批准号:
      24791431
    • 项目类别:
      Grant-in-Aid for Young Scientists (B)
    • 资助金额:
      $2.75万
    • 财政年份:
      2012
    • 负责人:
      ONIMARU Manabu
    • 依托单位:
    海外基金